CompanyBEIGF ONCNasdaq, OTCBasel

BeiGene

BeGene develops oncology treatments for hematologic and solid tumors.

SEC EDGAR ClinicalTrials.gov sse.com

8-KSep 23Latest SEC filing, period to Sep 23

Sep 11Latest story

September 2026

Trial tests Tislelizumab plus Anlotinib as consolidation therapy in limited-stage SCLC

Sep 11Trial updateBeiGene Sino Biopharmaceutical

BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancers

Sep 2Trial updateBeiGene tislelizumab

August 2026

BeOne Medicines files STAR Market interim report, discloses R&D spend by product under US GAAP

Aug 26Quarterly updateBeiGene

FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancer

Aug 25Regulatory decisionBeiGene Jazz Pharmaceuticals

BeOne Medicines reports Q2 2026 results, raises full-year revenue guidance

Aug 5Quarterly updateBeiGene sonrotoclax

July 2026

BeOne Medicines registers Phase 2 tislelizumab dosing study in Japanese ESCC patients

Jul 29Trial updateBeiGene tislelizumab

BeOne Medicines registers Phase 1 bioavailability study for PRMT5 inhibitor BGB-58067

Jul 17Weekly roundup, 2 itemsalcestobart BeiGene

June 2026

BeiGene's LBL-007/tislelizumab colorectal cancer trial posts results

Jun 30Trial updatealcestobart BeiGene